Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 2562

BillFederalHouseIn Committee
Making Pharmaceutical Markets More Competitive Act
About This Bill
Committee
Latest Action · May 26, 2017
Referred to the Subcommittee on Health.
Congress
115th (2017–2019)
Introduced
May 19, 2017
Cosponsors (0)
None
View PDF ↗

Summary

Highlight any text to annotate
Making Pharmaceutical Markets More Competitive Act This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs. The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale. The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.